Pfizer (PFE) Stock Price, Fundamentals & Analysis

What PFE does

Pfizer (PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. Its portfolio includes internal medicine products such as cardiovascular metabolic treatments under the Eliquis brand, migraine treatments under the Nurtec ODT/Vydura and Zavzpret brands, vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands, and Paxlovid for the treatment of COVID-19. The company also provides inflammation and immunology products such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. Pfizer is part of the S&P 500 and operates in the same sector as peers such as Bristol Myers Squibb (BMY), Amgen (AMGN), and Thermo Fisher Scientific (TMO).

Key numbers explained

• 28.18 USD is the current share price, representing the cost to buy one share of Pfizer on the US market.
• The trailing P/E ratio of 36.6 compares the share price to the last 12 months of earnings per share (0.77 USD); a higher number can indicate the market expects future growth.
• The forward P/E ratio of 9.7 uses expected future earnings, which can look lower if analysts forecast a significant rise in profits.
• The dividend yield of 6.16% shows the annual dividend payment as a percentage of the share price; it is a measure of income return, not total return.
• The ex-dividend date of Jul 24, 2026 is the cutoff: you must own the stock before this date to receive the next dividend payment.
• A beta of 0.3 suggests the stock has historically been less volatile than the overall market.
• The debt-to-equity ratio of 74.3% indicates the company uses debt relative to shareholder equity; higher ratios can mean more financial leverage.
• The price-to-book ratio of 1.89 compares the share price to the company's book value per share, a basic measure of whether the market values the company above its accounting net assets.

Recent news

Headlines highlight Moderna reaching a new high on the CEO's statement that the company is more than a COVID vaccine play, and articles discussing high-yield dividends that may appear attractive but carry risks. Other stories compare AbbVie's recent messaging, explore the best case for Pfizer stock, and contrast Eli Lilly with Pfizer as a place to park pharmaceutical capital in 2027. One headline notes that Pfizer's international chief explained how the company's turnaround works and outlined potential directions for the stock.

What to watch

Investors in Pfizer (PFE) typically monitor sector trends in Healthcare and Drug Manufacturers - General, as well as regulatory decisions and patent timelines that affect drug revenue. The company's earnings release on Nov 3, 2026 will be a key date for updated guidance and outlook. Broader factors such as interest rates, currency movements, and policy changes in the US and international markets can also influence the stock's performance. Comparing Pfizer with peers like Bristol Myers Squibb (BMY), Amgen (AMGN), or Thermo Fisher Scientific (TMO) can provide context for relative valuation and growth expectations.